1	PHARMACEUTICAL DISPENSING AMENDMENTS
2	2014 GENERAL SESSION
3	STATE OF UTAH
4	Chief Sponsor: Evan J. Vickers
5	House Sponsor: Stewart Barlow
6 7	LONG TITLE
8	General Description:
9	This bill amends the Pharmacy Practice Act to create a dispensing medical practitioner
10	license and a license classification for a dispensing medical practitioner clinic
11	pharmacy.
12	Highlighted Provisions:
13	This bill:
13	→ defines terms;
15	 establishes the license classification "dispensing medical practitioner" under the
16	Pharmacy Practice Act for medical practitioners who prescribe and dispense a drug;
17	
	• establishes the pharmacy facility license classification "dispensing medical
18	practitioner clinic pharmacy" under the Pharmacy Practice Act;
19	 creates Part 8, Dispensing Medical Practitioner and Dispensing Medical Practitioner
20	Clinic Pharmacy;
21	removes the exemption from the Pharmacy Practice Act for medical practitioners
22	who prescribe and dispense a cosmetic drug, injectable weight loss drug, or a cancer
23	drug treatment regimen;
24	requires a license as a dispensing medical practitioner for a health care practitioner
25	to dispense:



26	a cosmetic drug:
27	 a cancer drug treatment regimen; or
28	 a prepackaged drug at an employer sponsored clinic;
29	 requires the Board of Pharmacy to work in conjunction with the affected
30	practitioner governing boards:
31	 for discipline or hearings related to a dispensing medical practitioner; and
32	• to develop the administrative rules in the Pharmacy Practice Act related to a
33	dispensing medical practitioner and a dispensing medical practitioner clinic
34	pharmacy;
35	establishes that practice as a dispensing medical practitioner does not include:
36	 the use of a vending-type dispensing device; or
37	• the prescription of controlled substances, except as permitted for cancer drug
38	treatment regimens;
39	 amends the reporting requirements for the controlled substance database;
40	 amends unlawful and unprofessional conduct provisions; and
41	makes technical changes.
42	Money Appropriated in this Bill:
43	None
44	Other Special Clauses:
45	This bill takes effect on July 1, 2014.
46	Utah Code Sections Affected:
47	AMENDS:
48	58-17b-102, as last amended by Laws of Utah 2013, Chapters 52, 166, and 423
49	58-17b-301, as last amended by Laws of Utah 2013, Chapter 52
50	58-17b-302, as last amended by Laws of Utah 2013, Chapter 52
51	58-17b-309, as last amended by Laws of Utah 2013, Chapter 278
52	58-17b-309.6, as enacted by Laws of Utah 2013, Chapter 52
53	58-17b-612, as last amended by Laws of Utah 2013, Chapters 52 and 166
54	58-31b-502, as last amended by Laws of Utah 2012, Chapter 234
55	58-37f-203 , as enacted by Laws of Utah 2010, Chapter 287
56	58-67-502, as last amended by Laws of Utah 2012, Chapter 234

- 57 58-68-502, as last amended by Laws of Utah 2012, Chapter 234 58 58-70a-502, as last amended by Laws of Utah 2012, Chapter 234 59 58-70a-503, as last amended by Laws of Utah 2010, Chapter 37 60 58-83-502, as last amended by Laws of Utah 2012, Chapter 344 61 63I-1-258, as last amended by Laws of Utah 2013, Chapters 55, 87, 222, 278, and 351 62 **ENACTS**: 63 **58-17b-801**, Utah Code Annotated 1953 64 **58-17b-802**, Utah Code Annotated 1953 65 **58-17b-803**, Utah Code Annotated 1953 66 **58-17b-804**, Utah Code Annotated 1953 67 **58-17b-805**, Utah Code Annotated 1953 68 **58-17b-806.** Utah Code Annotated 1953 69 **REPEALS:** 70 58-17b-309.5, as enacted by Laws of Utah 2012, Chapter 234 71 72 *Be it enacted by the Legislature of the state of Utah:* 73 Section 1. Section 58-17b-102 is amended to read: 74 **58-17b-102.** Definitions. 75 In addition to the definitions in Section 58-1-102, as used in this chapter: 76 (1) "Administering" means: 77 (a) the direct application of a prescription drug or device, whether by injection, 78 inhalation, ingestion, or by any other means, to the body of a human patient or research subject 79 by another person; or 80 (b) the placement by a veterinarian with the owner or caretaker of an animal or group of animals of a prescription drug for the purpose of injection, inhalation, ingestion, or any other 81 82 means directed to the body of the animal by the owner or caretaker in accordance with written 83
 - (2) "Adulterated drug or device" means a drug or device considered adulterated under 21 U.S.C.S. Sec. 351 (2003).

or verbal directions of the veterinarian.

84

85

86 87

(3) (a) "Analytical laboratory" means a facility in possession of prescription drugs for the purpose of analysis.

- (b) "Analytical laboratory" does not include a laboratory possessing prescription drugs used as standards and controls in performing drug monitoring or drug screening analysis if the prescription drugs are prediluted in a human or animal body fluid, human or animal body fluid components, organic solvents, or inorganic buffers at a concentration not exceeding one milligram per milliliter when labeled or otherwise designated as being for in vitro diagnostic use.
- (4) "Animal euthanasia agency" means an agency performing euthanasia on animals by the use of prescription drugs.
- (5) "Automated pharmacy systems" includes mechanical systems which perform operations or activities, other than compounding or administration, relative to the storage, packaging, dispensing, or distribution of medications, and which collect, control, and maintain all transaction information.
- (6) "Beyond use date" means the date determined by a pharmacist and placed on a prescription label at the time of dispensing that indicates to the patient or caregiver a time beyond which the contents of the prescription are not recommended to be used.
- (7) "Board of pharmacy" or "board" means the Utah State Board of Pharmacy created in Section 58-17b-201.
- (8) "Branch pharmacy" means a pharmacy or other facility in a rural or medically underserved area, used for the storage and dispensing of prescription drugs, which is dependent upon, stocked by, and supervised by a pharmacist in another licensed pharmacy designated and approved by the division as the parent pharmacy.
- (9) "Centralized prescription processing" means the processing by a pharmacy of a request from another pharmacy to fill or refill a prescription drug order or to perform processing functions such as dispensing, drug utilization review, claims adjudication, refill authorizations, and therapeutic interventions.
- (10) "Class A pharmacy" means a pharmacy located in Utah that is authorized as a retail pharmacy to compound or dispense a drug or dispense a device to the public under a prescription order.
 - (11) "Class B pharmacy":
 - (a) means a pharmacy located in Utah:
 - (i) that is authorized to provide pharmaceutical care for patients in an institutional

119 setting; and

- (ii) whose primary purpose is to provide a physical environment for patients to obtain health care services; and
 - (b) (i) includes closed-door, hospital, clinic, nuclear, and branch pharmacies; and
 - (ii) pharmaceutical administration and sterile product preparation facilities.
- (12) "Class C pharmacy" means a pharmacy located in Utah that is authorized to engage in the manufacture, production, wholesale, or distribution of drugs or devices.
 - (13) "Class D pharmacy" means a nonresident pharmacy.
 - (14) "Class E pharmacy" means all other pharmacies.
- (15) "Closed-door pharmacy" means a pharmacy that provides pharmaceutical care to a defined and exclusive group of patients who have access to the services of the pharmacy because they are treated by or have an affiliation with a specific entity, including a health maintenance organization or an infusion company, but not including a hospital pharmacy, a retailer of goods to the general public, or the office of a practitioner.
- (16) "Collaborative pharmacy practice" means a practice of pharmacy whereby one or more pharmacists have jointly agreed, on a voluntary basis, to work in conjunction with one or more practitioners under protocol whereby the pharmacist may perform certain pharmaceutical care functions authorized by the practitioner or practitioners under certain specified conditions or limitations.
- (17) "Collaborative pharmacy practice agreement" means a written and signed agreement between one or more pharmacists and one or more practitioners that provides for collaborative pharmacy practice for the purpose of drug therapy management of patients and prevention of disease of human subjects.
- (18) (a) "Compounding" means the preparation, mixing, assembling, packaging, or labeling of a limited quantity drug, sterile product, or device:
- (i) as the result of a practitioner's prescription order or initiative based on the practitioner, patient, or pharmacist relationship in the course of professional practice;
- (ii) for the purpose of, or as an incident to, research, teaching, or chemical analysis and not for sale or dispensing; or
- (iii) in anticipation of prescription drug orders based on routine, regularly observed prescribing patterns.

150	(b) "Compounding" does not include:
151	(i) the preparation of prescription drugs by a pharmacist or pharmacy intern for sale to
152	another pharmacist or pharmaceutical facility;
153	(ii) the preparation by a pharmacist or pharmacy intern of any prescription drug in a
154	dosage form which is regularly and commonly available from a manufacturer in quantities and
155	strengths prescribed by a practitioner; or
156	(iii) the preparation of a prescription drug, sterile product, or device which has been
157	withdrawn from the market for safety reasons.
158	(19) "Confidential information" has the same meaning as "protected health
159	information" under the Standards for Privacy of Individually Identifiable Health Information,
160	45 C.F.R. Parts 160 and 164.
161	(20) "Controlled substance" has the same definition as in Section 58-37-2.
162	(21) "Dietary supplement" has the same meaning as Public Law Title 103, Chapter
163	417, Sec. 3a(ff) which is incorporated by reference.
164	(22) "Dispense" means the interpretation, evaluation, and implementation of a
165	prescription drug order or device or nonprescription drug or device under a lawful order of a
166	practitioner in a suitable container appropriately labeled for subsequent administration to or use
167	by a patient, research subject, or an animal.
168	(23) "Dispensing medical practitioner" means an individual who is:
169	(a) currently licensed as:
170	(i) a physician and surgeon under Chapter 67, Utah Medical Practice Act;
171	(ii) an osteopathic physician and surgeon under Chapter 68, Utah Osteopathic Medical
172	Practice Act;
173	(iii) a physician assistant under Chapter 70a, Physician Assistant Act;
174	(iv) a nurse practitioner under Chapter 31b, Nurse Practice Act; or
175	(v) an optometrist under Chapter 16a, Utah Optometry Practice Act, if the optometrist
176	is acting within the scope of practice for an optometrist; and
177	(b) licensed by the division under the Pharmacy Practice Act to engage in the practice
178	of a dispensing medical practitioner.
179	(24) "Dispensing medical practitioner clinic pharmacy" means a closed-door pharmacy
180	located within a licensed dispensing medical practitioner's place of practice.

181	$\left[\frac{(23)}{(25)}\right]$ "Distribute" means to deliver a drug or device other than by administering
182	or dispensing.
183	$[\frac{(24)}{2}]$ (26) (a) "Drug" means:
184	(i) a substance recognized in the official United States Pharmacopoeia, Official
185	Homeopathic Pharmacopoeia of the United States, or Official National Formulary, or any
186	supplement to any of them, intended for use in the diagnosis, cure, mitigation, treatment, or
187	prevention of disease in humans or animals;
188	(ii) a substance that is required by any applicable federal or state law or rule to be
189	dispensed by prescription only or is restricted to administration by practitioners only;
190	(iii) a substance other than food intended to affect the structure or any function of the
191	body of humans or other animals; and
192	(iv) substances intended for use as a component of any substance specified in
193	Subsections [(24)] (26)(a)(i), (ii), (iii), and (iv).
194	(b) "Drug" does not include dietary supplements.
195	$[\frac{(25)}{2}]$ "Drug regimen review" includes the following activities:
196	(a) evaluation of the prescription drug order and patient record for:
197	(i) known allergies;
198	(ii) rational therapy-contraindications;
199	(iii) reasonable dose and route of administration; and
200	(iv) reasonable directions for use;
201	(b) evaluation of the prescription drug order and patient record for duplication of
202	therapy;
203	(c) evaluation of the prescription drug order and patient record for the following
204	interactions:
205	(i) drug-drug;
206	(ii) drug-food;
207	(iii) drug-disease; and
208	(iv) adverse drug reactions; and
209	(d) evaluation of the prescription drug order and patient record for proper utilization,
210	including over- or under-utilization, and optimum therapeutic outcomes.
211	[(26)] (28) "Drug sample" means a prescription drug packaged in small quantities

- consistent with limited dosage therapy of the particular drug, which is marked "sample", is not intended to be sold, and is intended to be provided to practitioners for the immediate needs of patients for trial purposes or to provide the drug to the patient until a prescription can be filled by the patient.
- [(27)] (29) "Electronic signature" means a trusted, verifiable, and secure electronic sound, symbol, or process attached to or logically associated with a record and executed or adopted by a person with the intent to sign the record.
- [(28)] (30) "Electronic transmission" means transmission of information in electronic form or the transmission of the exact visual image of a document by way of electronic equipment.
- [(29)] (31) "Hospital pharmacy" means a pharmacy providing pharmaceutical care to inpatients of a general acute hospital or specialty hospital licensed by the Department of Health under Title 26, Chapter 21, Health Care Facility Licensing and Inspection Act.
 - [(30)] (32) "Legend drug" has the same meaning as prescription drug.
- [(31)] (33) "Licensed pharmacy technician" means an individual licensed with the division, that may, under the supervision of a pharmacist, perform the activities involved in the technician practice of pharmacy.
- [(32)] (34) "Manufacturer" means a person or business physically located in Utah licensed to be engaged in the manufacturing of drugs or devices.
 - $\left[\frac{(33)}{(35)}\right]$ (a) "Manufacturing" means:
- (i) the production, preparation, propagation, conversion, or processing of a drug or device, either directly or indirectly, by extraction from substances of natural origin or independently by means of chemical or biological synthesis, or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its container; and
 - (ii) the promotion and marketing of such drugs or devices.
- (b) "Manufacturing" includes the preparation and promotion of commercially available products from bulk compounds for resale by pharmacies, practitioners, or other persons.
- (c) "Manufacturing" does not include the preparation or compounding of a drug by a pharmacist, pharmacy intern, or practitioner for that individual's own use or the preparation, compounding, packaging, labeling of a drug, or incident to research, teaching, or chemical

243	anarysis.
244	[(34)] (36) "Medical order" means a lawful order of a practitioner which may include a
245	prescription drug order.
246	[(35)] (37) "Medication profile" or "profile" means a record system maintained as to
247	drugs or devices prescribed for a pharmacy patient to enable a pharmacist or pharmacy intern to
248	analyze the profile to provide pharmaceutical care.
249	[(36)] (38) "Misbranded drug or device" means a drug or device considered
250	misbranded under 21 U.S.C.S. Sec. 352 (2003).
251	[(37)] (39) (a) "Nonprescription drug" means a drug which:
252	(i) may be sold without a prescription; and
253	(ii) is labeled for use by the consumer in accordance with federal law.
254	(b) "Nonprescription drug" includes homeopathic remedies.
255	[(38)] (40) "Nonresident pharmacy" means a pharmacy located outside of Utah that
256	sells to a person in Utah.
257	[(39)] (41) "Nuclear pharmacy" means a pharmacy providing radio-pharmaceutical
258	service.
259	[(40)] (42) "Out-of-state mail service pharmacy" means a pharmaceutical facility
260	located outside the state that is licensed and in good standing in another state, that:
261	(a) ships, mails, or delivers by any lawful means a dispensed legend drug to a patient in
262	this state pursuant to a lawfully issued prescription;
263	(b) provides information to a patient in this state on drugs or devices which may
264	include, but is not limited to, advice relating to therapeutic values, potential hazards, and uses;
265	or
266	(c) counsels pharmacy patients residing in this state concerning adverse and therapeutic
267	effects of drugs.
268	$\left[\frac{(41)}{(43)}\right]$ "Patient counseling" means the written and oral communication by the
269	pharmacist or pharmacy intern of information, to the patient or caregiver, in order to ensure
270	proper use of drugs, devices, and dietary supplements.
271	[(42)] (44) "Pharmaceutical administration facility" means a facility, agency, or
272	institution in which:
273	(a) prescription drugs or devices are held, stored, or are otherwise under the control of

274 the facility or agency for administration to patients of that facility or agency;

- (b) prescription drugs are dispensed to the facility or agency by a licensed pharmacist or pharmacy intern with whom the facility has established a prescription drug supervising relationship under which the pharmacist or pharmacy intern provides counseling to the facility or agency staff as required, and oversees drug control, accounting, and destruction; and
- (c) prescription drugs are professionally administered in accordance with the order of a practitioner by an employee or agent of the facility or agency.
- [(43)] (45) (a) "Pharmaceutical care" means carrying out the following in collaboration with a prescribing practitioner, and in accordance with division rule:
- (i) designing, implementing, and monitoring a therapeutic drug plan intended to achieve favorable outcomes related to a specific patient for the purpose of curing or preventing the patient's disease;
 - (ii) eliminating or reducing a patient's symptoms; or
 - (iii) arresting or slowing a disease process.
- (b) "Pharmaceutical care" does not include prescribing of drugs without consent of a prescribing practitioner.
- [(44)] (46) "Pharmaceutical facility" means a business engaged in the dispensing, delivering, distributing, manufacturing, or wholesaling of prescription drugs or devices within or into this state.
- [(45)] (47) (a) "Pharmaceutical wholesaler or distributor" means a pharmaceutical facility engaged in the business of wholesale vending or selling of a prescription drug or device to other than a consumer or user of the prescription drug or device that the pharmaceutical facility has not produced, manufactured, compounded, or dispensed.
- (b) "Pharmaceutical wholesaler or distributor" does not include a pharmaceutical facility carrying out the following business activities:
 - (i) intracompany sales;
- (ii) the sale, purchase, or trade of a prescription drug or device, or an offer to sell, purchase, or trade a prescription drug or device, if the activity is carried out between one or more of the following entities under common ownership or common administrative control, as defined by division rule:
 - (A) hospitals;

305	(B) pharmacies;
306	(C) chain pharmacy warehouses, as defined by division rule; or
307	(D) other health care entities, as defined by division rule;
308	(iii) the sale, purchase, or trade of a prescription drug or device, or an offer to sell,
309	purchase, or trade a prescription drug or device, for emergency medical reasons, including
310	supplying another pharmaceutical facility with a limited quantity of a drug, if:
311	(A) the facility is unable to obtain the drug through a normal distribution channel in
312	sufficient time to eliminate the risk of harm to a patient that would result from a delay in
313	obtaining the drug; and
314	(B) the quantity of the drug does not exceed an amount reasonably required for
315	immediate dispensing to eliminate the risk of harm;
316	(iv) the distribution of a prescription drug or device as a sample by representatives of
317	manufacturer; and
318	(v) the distribution of prescription drugs, if:
319	(A) the dosage units distributed during a calendar year do not exceed five percent of
320	the sum of the dosage units distributed by the facility during the calendar year and the dosage
321	units dispensed by the facility during the calendar year; and
322	(B) the distribution otherwise complies with 21 C.F.R. Sec. 1307.11.
323	[(46)] (48) "Pharmacist" means an individual licensed by this state to engage in the
324	practice of pharmacy.
325	[(47)] (49) "Pharmacist-in-charge" means a pharmacist currently licensed in good
326	standing who accepts responsibility for the operation of a pharmacy in conformance with all
327	laws and rules pertinent to the practice of pharmacy and the distribution of drugs, and who is
328	personally in full and actual charge of the pharmacy and all personnel.
329	[(48)] (50) "Pharmacist preceptor" means a licensed pharmacist in good standing with
330	one or more years of licensed experience. The preceptor serves as a teacher, example of
331	professional conduct, and supervisor of interns in the professional practice of pharmacy.
332	[(49)] <u>(51)</u> "Pharmacy" means any place where:
333	(a) drugs are dispensed;
334	(b) pharmaceutical care is provided;
335	(c) drugs are processed or handled for eventual use by a patient; or

336	(d) drugs are used for the purpose of analysis or research.
337	[(50)] (52) "Pharmacy benefits manager or coordinator" means a person or entity that
338	provides pharmacy benefit management services as defined in Section 49-20-502 on behalf of a
339	self-insured employer, insurance company, health maintenance organization, or other plan
340	sponsor, as defined by rule.
341	[(51)] (53) "Pharmacy intern" means an individual licensed by this state to engage in
342	practice as a pharmacy intern.
343	[(52)] (54) "Pharmacy technician training program" means an approved technician
344	training program providing education for pharmacy technicians.
345	(55) (a) "Practice as a dispensing medical practitioner" means the practice of pharmacy,
346	specifically relating to the dispensing of a prescription drug in accordance with Part 8,
347	Dispensing Medical Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, and
348	division rule adopted after consultation with the Board of Pharmacy and the governing boards
349	of the practitioners described in Subsection (23)(a).
350	(b) "Practice as a dispensing medical practitioner" does not include:
351	(i) using a vending-type of dispenser as defined by the division by administrative rule;
352	<u>or</u>
353	(ii) except as permitted by Section 58-17b-805, dispensing of a controlled substance as
354	defined in Section 58-37-2.
355	[(53)] (56) (a) "Practice as a licensed pharmacy technician" means engaging in practice
356	as a pharmacy technician under the general supervision of a licensed pharmacist and in
357	accordance with a scope of practice defined by division rule made in collaboration with the
358	board.
359	(b) "Practice as a licensed pharmacy technician" does not include:
360	(i) performing a drug utilization review, prescription drug order clarification from a
361	prescriber, final review of the prescription, dispensing of the drug, or counseling a patient with
362	respect to a prescription drug;
363	(ii) except as permitted by rules made by the division in consultation with the board,
364	final review of a prescribed drug prepared for dispensing;
365	(iii) counseling regarding nonprescription drugs and dietary supplements unless
366	delegated by the supervising pharmacist; or

36/	(iv) receiving new prescription drug orders when communicating telephonically or
368	electronically unless the original information is recorded so the pharmacist may review the
369	prescription drug order as transmitted.
370	[(54)] (57) "Practice of pharmacy" includes the following:
371	(a) providing pharmaceutical care;
372	(b) collaborative pharmacy practice in accordance with a collaborative pharmacy
373	practice agreement;
374	(c) compounding, packaging, labeling, dispensing, administering, and the coincident
375	distribution of prescription drugs or devices, provided that the administration of a prescription
376	drug or device is:
377	(i) pursuant to a lawful order of a practitioner when one is required by law; and
378	(ii) in accordance with written guidelines or protocols:
379	(A) established by the licensed facility in which the prescription drug or device is to be
380	administered on an inpatient basis; or
381	(B) approved by the division, in collaboration with the board and the Physicians
382	Licensing Board, created in Section 58-67-201, if the prescription drug or device is to be
383	administered on an outpatient basis solely by a licensed pharmacist;
384	(d) participating in drug utilization review;
385	(e) ensuring proper and safe storage of drugs and devices;
386	(f) maintaining records of drugs and devices in accordance with state and federal law
387	and the standards and ethics of the profession;
388	(g) providing information on drugs or devices, which may include advice relating to
389	therapeutic values, potential hazards, and uses;
390	(h) providing drug product equivalents;
391	(i) supervising pharmacist's supportive personnel, pharmacy interns, and pharmacy
392	technicians;
393	(j) providing patient counseling, including adverse and therapeutic effects of drugs;
394	(k) providing emergency refills as defined by rule;
395	(l) telepharmacy; and
396	(m) formulary management intervention.
397	[(55)] (58) "Practice of telepharmacy" means the practice of pharmacy through the use

398	of telecommunications and information technologies.
399	[(56)] (59) "Practice of telepharmacy across s

[(56)] (59) "Practice of telepharmacy across state lines" means the practice of pharmacy through the use of telecommunications and information technologies that occurs when the patient is physically located within one jurisdiction and the pharmacist is located in another jurisdiction.

[(57)] (60) "Practitioner" means an individual currently licensed, registered, or otherwise authorized by the appropriate jurisdiction to prescribe and administer drugs in the course of professional practice.

[(58)] (61) "Prescribe" means to issue a prescription:

- (a) orally or in writing; or
- (b) by telephone, facsimile transmission, computer, or other electronic means of communication as defined by division rule.

[(59)] (62) "Prescription" means an order issued:

- (a) by a licensed practitioner in the course of that practitioner's professional practice or by collaborative pharmacy practice agreement; and
- (b) for a controlled substance or other prescription drug or device for use by a patient or an animal.

[(60)] (63) "Prescription device" means an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, and any component part or accessory, which is required under federal or state law to be prescribed by a practitioner and dispensed by or through a person or entity licensed under this chapter or exempt from licensure under this chapter.

[(61)] (64) "Prescription drug" means a drug that is required by federal or state law or rule to be dispensed only by prescription or is restricted to administration only by practitioners.

[(62)] (65) "Research using pharmaceuticals" means research:

- (a) conducted in a research facility, as defined by division rule, that is associated with a university or college in the state accredited by the Northwest Commission on Colleges and Universities;
- (b) requiring the use of a controlled substance, prescription drug, or prescription device;
- (c) that uses the controlled substance, prescription drug, or prescription device in

429	accordance with standard research protocols and techniques, including, if required, those
430	approved by an institutional review committee; and
431	(d) that includes any documentation required for the conduct of the research and the
432	handling of the controlled substance, prescription drug, or prescription device.
433	[(63)] (66) "Retail pharmacy" means a pharmaceutical facility dispensing prescription
434	drugs and devices to the general public.
435	[(64)] (67) "Self-audit" means an internal evaluation of a pharmacy to determine
436	compliance with this chapter.
437	[(65)] (68) "Supervising pharmacist" means a pharmacist who is overseeing the
438	operation of the pharmacy during a given day or shift.
439	[(66)] (69) "Supportive personnel" means unlicensed individuals who:
440	(a) may assist a pharmacist, pharmacist preceptor, pharmacy intern, or licensed
441	pharmacy technician in nonjudgmental duties not included in the definition of the practice of
442	pharmacy, practice of a pharmacy intern, or practice of a licensed pharmacy technician, and as
443	those duties may be further defined by division rule adopted in collaboration with the board;
444	and
445	(b) are supervised by a pharmacist in accordance with rules adopted by the division in
446	collaboration with the board.
447	[(67)] (70) "Unlawful conduct" is as defined in Sections 58-1-501 and 58-17b-501.
448	[(68)] (71) "Unprofessional conduct" is as defined in Sections 58-1-501 and
449	58-17b-502 and may be further defined by rule.
450	[(69)] (72) "Veterinary pharmaceutical facility" means a pharmaceutical facility that
451	dispenses drugs intended for use by animals or for sale to veterinarians for the administration
452	for animals.
453	Section 2. Section 58-17b-301 is amended to read:
454	58-17b-301. License required License classifications for individuals.
455	(1) A license is required to engage in the practice of pharmacy, telepharmacy, [or the
456	practice of a] pharmacy technician, or dispensing medical practitioner except as specifically
457	provided in Section 58-1-307[,] or 58-17b-309[, or 58-17-309.6].
458	(2) The division shall issue to an individual who qualifies under this chapter a license
459	in the classification of:

460	(a) pharmacist;
461	(b) pharmacy intern; [or]
462	(c) pharmacy technician[-]; or
463	(d) dispensing medical practitioner.
464	Section 3. Section 58-17b-302 is amended to read:
465	58-17b-302. License required License classifications for pharmacy facilities.
466	(1) A license is required to act as a pharmacy, except as specifically exempted from
467	licensure under Section 58-1-307 [or 58-17-309.6].
468	(2) The division shall issue a pharmacy license to a facility that qualifies under this
469	chapter in the classification of a:
470	(a) class A pharmacy;
471	(b) class B pharmacy;
472	(c) class C pharmacy;
473	(d) class D pharmacy; [or]
474	(e) class E pharmacy[-]; or
475	(f) dispensing medical practitioner clinic pharmacy.
476	(3) Each place of business shall require a separate license. If multiple pharmacies exist
477	at the same address, a separate license shall be required for each pharmacy.
478	(4) The division may further define or supplement the classifications of pharmacies.
479	The division may impose restrictions upon classifications to protect the public health, safety,
480	and welfare.
481	(5) Each pharmacy shall have a pharmacist-in-charge, except as otherwise provided by
482	rule.
483	(6) Whenever an applicable statute or rule requires or prohibits action by a pharmacy,
484	the pharmacist-in-charge and the owner of the pharmacy shall be responsible for all activities
485	of the pharmacy, regardless of the form of the business organization.
486	Section 4. Section 58-17b-309 is amended to read:
487	58-17b-309. Exemptions from licensure.
488	[(1) For purposes of this section:]
489	[(a) "Cosmetic drug":]
490	[(i) means a prescription drug that is:]

491	[(A) for the purpose of promoting attractiveness or altering the appearance of an
492	individual; and]
493	[(B) listed as a cosmetic drug subject to the exemption under this section by the
494	division by administrative rule or has been expressly approved for online dispensing, whether
495	or not it is dispensed online or through a physician's office; and]
496	[(ii) does not include a prescription drug that is:]
497	[(A) a controlled substance;]
498	[(B) compounded by the physician; or]
499	[(C) prescribed or used for the patient for the purpose of diagnosing, curing, or
500	preventing a disease.]
501	[(b) "Injectable weight loss drug":]
502	[(i) means an injectable prescription drug:]
503	[(A) prescribed to promote weight loss; and]
504	[(B) listed as an injectable prescription drug subject to exemption under this section by
505	the division by administrative rule; and]
506	[(ii) does not include a prescription drug that is a controlled substance.]
507	[(c) "Prescribing practitioner" means an individual licensed under:]
508	[(i) Chapter 31b, Nurse Practice Act, as an advanced practice registered nurse with
509	prescriptive practice;]
510	[(ii) Chapter 67, Utah Medical Practice Act;]
511	[(iii) Chapter 68, Utah Osteopathic Medical Practice Act; or]
512	[(iv) Chapter 70a, Physician Assistant Act.]
513	[(2)] (1) In addition to the exemptions from licensure in [Sections] Section 58-1-307
514	[and 58-17b-309.5], the following individuals may engage in the acts or practices described in
515	this section without being licensed under this chapter:
516	[(a) if the individual is described in Subsections (2)(b), (d), or (e), the individual
517	notifies the division in writing of the individual's intent to dispense a drug under this
518	subsection;]
519	[(b)] (a) a person selling or providing contact lenses in accordance with Section
520	58-16a-801; <u>or</u>
521	[(c)] (b) an individual engaging in the practice of pharmacy technician under the direct

522	personal supervision of a pharmacist while making satisfactory progress in an approved
523	program as defined in division rule[;].
524	[(d) a prescribing practitioner who prescribes and dispenses a cosmetic drug or an
525	injectable weight loss drug to the prescribing practitioner's patient in accordance with
526	Subsection (4); or]
527	[(e) an optometrist, as defined in Section 58-16a-102, acting within the optometrist's
528	scope of practice as defined in Section 58-16a-601, who prescribes and dispenses a cosmetic
529	drug to the optometrist's patient in accordance with Subsection (4).]
530	[(3)] (2) In accordance with Subsection 58-1-303(1)(a), an individual exempt under
531	Subsection $[\frac{(2)(c)}{(1)(b)}]$ must take all examinations as required by division rule following
532	completion of an approved curriculum of education, within the required time frame. This
533	exemption expires immediately upon notification of a failing score of an examination, and the
534	individual may not continue working as a pharmacy technician even under direct supervision.
535	[(4) A prescribing practitioner or optometrist is exempt from licensing under the
536	provisions of this part if the prescribing practitioner or optometrist:]
537	[(a) (i) writes a prescription for a drug the prescribing practitioner or optometrist has
538	the authority to dispense under Subsection (4)(b); and]
539	[(ii) informs the patient:]
540	[(A) that the prescription may be filled at a pharmacy or dispensed in the prescribing
541	practitioner's or optometrist's office;]
542	[(B) of the directions for appropriate use of the drug;]
543	[(C) of potential side-effects to the use of the drug; and]
544	[(D) how to contact the prescribing practitioner or optometrist if the patient has
545	questions or concerns regarding the drug;
546	[(b) dispenses a cosmetic drug or injectable weight loss drug only to the prescribing
547	practitioner's patients or for an optometrist, dispenses a cosmetic drug only to the optometrist's
548	patients;]
549	[(c) follows labeling, record keeping, patient counseling, storage, purchasing and
550	distribution, operating, treatment, and quality of care requirements established by
551	administrative rule adopted by the division in consultation with the boards listed in Subsection
552	(5)(a); and]

553	[(d) follows USP-NF 797 standards for sterile compounding if the drug dispensed to
554	patients is reconstituted or compounded.]
555	[(5) (a) The division, in consultation with the board under this chapter and the relevant
556	professional board, including the Physician Licensing Board, the Osteopathic Physician
557	Licensing Board, the Physician Assistant Licensing Board, the Board of Nursing, the
558	Optometrist Licensing Board, or the Online Prescribing, Dispensing, and Facilitation Board,
559	shall adopt administrative rules pursuant to Title 63G, Chapter 3, Utah Administrative
560	Rulemaking Act to designate:
561	[(i) the prescription drugs that may be dispensed as a cosmetic drug or weight loss drug
562	under this section; and]
563	[(ii) the requirements under Subsection (4)(c).]
564	[(b) When making a determination under Subsection (1)(a), the division and boards
565	listed in Subsection (5)(a) may consider any federal Food and Drug Administration indications
566	or approval associated with a drug when adopting a rule to designate a prescription drug that
567	may be dispensed under this section.]
568	[(c) The division may inspect the office of a prescribing practitioner or optometrist
569	who is dispensing under the provisions of this section, in order to determine whether the
570	prescribing practitioner or optometrist is in compliance with the provisions of this section. If a
571	prescribing practitioner or optometrist chooses to dispense under the provisions of this section,
572	the prescribing practitioner or optometrist consents to the jurisdiction of the division to inspect
573	the prescribing practitioner's or optometrist's office and determine if the provisions of this
574	section are being met by the prescribing practitioner or optometrist.]
575	[(d) If a prescribing practitioner or optometrist violates a provision of this section, the
576	prescribing practitioner or optometrist may be subject to discipline under:]
577	[(i) this chapter; and]
578	[(ii) (A) Chapter 16a, Utah Optometry Practice Act;]
579	[(B) Chapter 31b, Nurse Practice Act;]
580	[(C) Chapter 67, Utah Medical Practice Act;]
581	[(D) Chapter 68, Utah Osteopathic Medical Practice Act;]
582	[(E) Chapter 70a, Physician Assistant Act; or]
583	[(F) Chapter 83, Online Prescribing, Dispensing, and Facilitation Act.]

584	[(6) Except as provided in Subsection (2)(e), this section does not restrict or limit the
585	scope of practice of an optometrist or optometric physician licensed under Chapter 16a, Utah
586	Optometry Practice Act.]
587	Section 5. Section 58-17b-309.6 is amended to read:
588	58-17b-309.6. Exemptions from licensure for research using pharmaceuticals.
589	Research using pharmaceuticals, as defined in Subsection 58-17b-102[(64)](65), is
590	exempt from licensure under Sections 58-17b-301 and 58-17b-302.
591	Section 6. Section 58-17b-612 is amended to read:
592	58-17b-612. Supervision Pharmacist-in-charge.
593	(1) (a) Any pharmacy, except a wholesaler, distributor, out-of-state mail service
594	pharmacy, or class E pharmacy, shall be under the general supervision of at least one
595	pharmacist licensed to practice in Utah. One pharmacist licensed in Utah shall be designated
596	as the pharmacist-in-charge, whose responsibility it is to oversee the operation of the pharmacy
597	(b) Notwithstanding Subsection 58-17b-102[(65)](68), a supervising pharmacist does
598	not have to be in the pharmacy or care facility but shall be available via a telepharmacy system
599	for immediate contact with the supervised pharmacy technician or pharmacy intern if:
500	(i) the pharmacy is located in:
501	(A) a remote rural hospital, as defined in Section 26-21-13.6; or
502	(B) a clinic located in a remote rural county with less than 20 people per square mile;
503	(ii) the supervising pharmacist described in Subsection (1)(a) is not available; and
504	(iii) the telepharmacy system maintains records and files quarterly reports as required
505	by division rule to assure that patient safety is not compromised.
606	(2) Each out-of-state mail service pharmacy shall designate and identify to the division
507	a pharmacist holding a current license in good standing issued by the state in which the
608	pharmacy is located and who serves as the pharmacist-in-charge for all purposes under this
509	chapter.
510	Section 7. Section 58-17b-801 is enacted to read:
511	Part 8. Dispensing Medical Practitioner and Dispensing Medical
512	Practitioner Clinic Pharmacy
513	<u>58-17b-801.</u> Title.
514	This part is known as "Dispensing Medical Practitioner and Dispensing Medical

615	Practitioner Clinic Pharmacy."
616	Section 8. Section 58-17b-802 is enacted to read:
617	58-17b-802. Definitions.
618	As used in this part:
619	(1) (a) "Cosmetic drug" means a prescription drug that:
620	(i) is for the purpose of promoting attractiveness or altering the appearance of an
621	individual; and
622	(ii) (A) is listed as a cosmetic drug subject to the exemption under this section by the
623	division by administrative rule; or
624	(B) has been expressly approved for online dispensing, whether or not it is dispensed
625	online or through a physician's office.
626	(b) "Cosmetic drug" does not include a prescription drug that is:
627	(i) a controlled substance;
628	(ii) compounded by the physician; or
629	(iii) prescribed or used for the patient for the purpose of diagnosing, curing, or
630	preventing a disease.
631	(2) "Employer sponsored clinic" means an entity that offers health care only to the
632	employees of an exclusive group of employers and the employees' dependents.
633	(3) "Health care" is as defined in Section 31A-1-301
634	(4) (a) "Injectable weight loss drug" means an injectable prescription drug:
635	(i) prescribed to promote weight loss; and
636	(ii) listed as an injectable prescription drug subject to exemption under this section by
637	the division by administrative rule.
638	(b) "Injectable weight loss drug" does not include a prescription drug that is a
639	controlled substance.
640	(5) "Prepackaged drug" means a prescription drug that:
641	(a) is not listed under federal or state law as a Schedule I, II, III, IV, or V drug; and
642	(b) is packaged in a fixed quantity per package by:
643	(i) the drug manufacturer;
644	(ii) a pharmaceutical wholesaler or distributor; or
645	(iii) a pharmacy licensed under this title.

646	Section 9. Section 58-17b-803 is enacted to read:
647	58-17b-803. Qualifications for licensure as a dispensing medical practitioner
648	Scope of practice.
649	(1) An applicant for a license as a dispensing medical practitioner shall:
650	(a) be licensed in good standing under at least one of the chapters listed in Subsection
651	58-17b-102(23)(a); and
652	(b) submit an application for a license as a dispensing medical practitioner in a form
653	prescribed by the division and pay a fee established by the department.
654	(2) The division shall accept the licensing in good standing under Subsection (1) in lieu
655	of requiring an applicant for a license under this part to comply with Sections 58-17b-303 and
656	<u>58-17b-307.</u>
657	(3) A dispensing medical practitioner may dispense, in accordance with this part:
658	(a) a cosmetic drug and an injectable weight loss drug if:
659	(i) the drug was prescribed by the dispensing medical practitioner to the dispensing
660	medical practitioner's patient; and
661	(ii) the dispensing medical practitioner complies with administrative rules adopted by
662	the division under Subsection 58-17-802(1);
663	(b) a cancer drug treatment regimen if the dispensing medical practitioner complies
664	with Section 58-17b-805; and
665	(c) a pre-packaged drug to an employee or a dependent of an employee at an employer
666	sponsored clinic if the dispensing medical practitioner:
667	(i) treats an employee, or the dependent of an employee, of one of an exclusive group
668	of employers at an employer sponsored clinic;
669	(ii) prescribes a prepackaged drug to the employee or the employee's dependent;
670	(iii) dispenses the prepackaged drug at the employer sponsored clinic; and
671	(iv) complies with administrative rules adopted by the division in consultation with the
672	Board of Pharmacy that establish labeling, record keeping, patient counseling, purchasing and
673	distribution, operating, treatment, quality of care, and storage requirements.
674	(4) A dispensing medical practitioner:
675	(a) shall inform the patient:
676	(i) that the drug dispensed by the practitioner may be obtained from a pharmacy

677	unaffiliated with the practitioner;
678	(ii) of the directions for appropriate use of the dispensed drug;
679	(iii) of potential side effects to the use of the dispensed drug; and
680	(iv) how to contact the dispensing medical practitioner if the patient has questions or
681	concerns regarding the drug;
682	(b) shall report to the controlled substance database in the same manner as required in
683	Section 58-37f-203; and
684	(c) may delegate the dispensing of the drug if the individual to whom the dispensing
685	was delegated is:
686	(i) employed by the dispensing medical practitioner or the outpatient clinic setting in
687	which the dispensing medical practitioner works; and
688	(ii) acting under the direction of a dispensing medical practitioner who is immediately
689	available on site for any necessary consultation.
690	(5) If the chapter that governs the license of a dispensing medical practitioner, as listed
691	in Subsection 58-17b-102(23), requires physician supervision in its scope of practice
692	requirements, the dispensing medical practitioner shall only dispense a drug under the
693	supervision of an individual licensed under Chapter 67, Utah Medical Practice Act, or Chapter
694	68, Utah Osteopathic Medical Practice Act
695	Section 10. Section 58-17b-804 is enacted to read:
696	58-17b-804. Qualifications for licensure as a dispensing medical practitioner clinic
697	pharmacy.
698	(1) An applicant for a license as a dispensing medical practitioner clinic pharmacy shall
699	comply with Section 58-17b-306.
700	(2) (a) Notwithstanding Section 58-17b-302, a pharmacy licensed under this part is not
701	required to have a pharmacist-in-charge if:
702	(i) the pharmacy has designated a dispensing medical practitioner as responsible for all
703	activities of the pharmacy; and
704	(ii) the pharmacy complies with administrative rules adopted by the division in
705	consultation with the Board of Pharmacy and the governing bodies of the practitioners
706	described in Subsection 58-17b-102(23)(a).
707	(b) Notwithstanding Subsection 58-17b-306(1)(e), the division, in consultation with

708	the Board of Pharmacy and the governing boards of the practitioners described in Subsection
709	58-17b-102(23)(a), may modify the operating standards for a dispensing medical practitioner
710	clinic pharmacy.
711	Section 11. Section 58-17b-805 is enacted to read:
712	58-17b-805. Dispensing medical practitioner Cancer drug treatment regimen.
713	(1) For purposes of this section:
714	(a) "Cancer drug treatment regimen" means a prescription drug used to treat cancer,
715	manage its symptoms, or provide continuity of care for a cancer patient.
716	(b) "Cancer drug treatment regimen" includes:
717	(i) a chemotherapy drug administered intravenously, orally, rectally, or by dermal
718	methods; and
719	(ii) a drug used to support cancer treatment, including a drug to treat, alleviate, or
720	minimize physical and psychological symptoms or pain, or to improve patient tolerance of
721	cancer treatments or prepare a patient for a subsequent course of therapy.
722	(c) "Cancer drug treatment regimen" does not mean a drug listed under federal law as a
723	Schedule I, II, or III drug.
724	(2) An individual may be licensed as a dispensing medical practitioner with a scope of
725	practice that permits the dispensing medical practitioner to prescribe and dispense a cancer
726	drug treatment regimen if the individual:
727	(a) is licensed as described in Subsections 58-17b-102(23)(a)(i) and (ii); and
728	(b) is certified or eligible to be certified by the American Board of Internal Medicine in
729	medical oncology.
730	(3) A dispensing medical practitioner authorized to prescribe and dispense a cancer
731	drug treatment regimen under this section may prescribe and dispense a cancer drug treatment
732	regimen:
733	(a) to the practitioner's patient who is currently undergoing chemotherapy in an
734	outpatient clinic setting; and
735	(b) if the practitioner determines that providing the cancer drug treatment regimen to
736	the patient in the outpatient clinic setting is in the best interest of the patient or provides better
737	access to care for the patient.
738	Section 12 Section 58-17h-806 is enacted to read:

739	58-17b-806. Dispensing medical practitioner Dispensing medical practitioner
740	clinic pharmacy Unprofessional and Unlawful conduct.
741	(1) The division, in consultation with the board shall:
742	(a) report a violation of this chapter by a dispensing medical practitioner to the
743	dispensing medical practitioner's appropriate licensing board as designated in Subsection
744	58-17b-102(23)(a); and
745	(b) assist the licensing board for the dispensing medical practitioner with reviewing the
746	violations of the provisions of this chapter.
747	(2) The division, in collaboration with the Board of Pharmacy, may take appropriate
748	action against a dispensing medical practitioner, in accordance with this chapter, if the
749	licensing board designated in Subsection 58-17b-102(23)(a) recommends to the division that
750	action be taken under this chapter.
751	(3) The division, in consultation with the board is the primary enforcer under this
752	chapter for a dispensing medical practitioner clinic pharmacy licensed under Section
753	<u>58-17b-804.</u>
754	Section 13. Section 58-31b-502 is amended to read:
755	58-31b-502. Unprofessional conduct.
756	"Unprofessional conduct" includes:
757	(1) failure to safeguard a patient's right to privacy as to the patient's person, condition,
758	diagnosis, personal effects, or any other matter about which the licensee is privileged to know
759	because of the licensee's or person with a certification's position or practice as a nurse or
760	practice as a medication aide certified;
761	(2) failure to provide nursing service or service as a medication aide certified in a
762	manner that demonstrates respect for the patient's human dignity and unique personal character
763	and needs without regard to the patient's race, religion, ethnic background, socioeconomic
764	status, age, sex, or the nature of the patient's health problem;
765	(3) engaging in sexual relations with a patient during any:
766	(a) period when a generally recognized professional relationship exists between the
767	person licensed or certified under this chapter and patient; or
768	(b) extended period when a patient has reasonable cause to believe a professional
769	relationship exists between the person licensed or certified under the provisions of this chapter

and the patient;

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

- (4) (a) as a result of any circumstance under Subsection (3), exploiting or using information about a patient or exploiting the licensee's or the person with a certification's professional relationship between the licensee or holder of a certification under this chapter and the patient; or
- (b) exploiting the patient by use of the licensee's or person with a certification's knowledge of the patient obtained while acting as a nurse or a medication aide certified;
 - (5) unlawfully obtaining, possessing, or using any prescription drug or illicit drug;
 - (6) unauthorized taking or personal use of nursing supplies from an employer;
 - (7) unauthorized taking or personal use of a patient's personal property;
- (8) knowingly entering into any medical record any false or misleading information or altering a medical record in any way for the purpose of concealing an act, omission, or record of events, medical condition, or any other circumstance related to the patient and the medical or nursing care provided;
 - (9) unlawful or inappropriate delegation of nursing care;
- (10) failure to exercise appropriate supervision of persons providing patient care services under supervision of the licensed nurse;
- (11) employing or aiding and abetting the employment of an unqualified or unlicensed person to practice as a nurse;
- (12) failure to file or record any medical report as required by law, impeding or obstructing the filing or recording of such a report, or inducing another to fail to file or record such a report;
- (13) breach of a statutory, common law, regulatory, or ethical requirement of confidentiality with respect to a person who is a patient, unless ordered by a court;
 - (14) failure to pay a penalty imposed by the division;
- (15) prescribing a schedule II-III controlled substance without a consulting physician or outside of a consultation and referral plan;
 - (16) violating Section 58-31b-801; and
- 798 (17) violating the dispensing requirements of Section 58-17b-309 or [58-17b-309.5]
 799 Chapter 17b, Part 8, Dispensing Medical Practitioner and Dispensing Medical Practitioner

800 <u>Clinic Pharmacy</u>, if applicable.

801	Section 14. Section 58-3/1-203 is amended to read:
802	58-37f-203. Submission, collection, and maintenance of data.
803	(1) (a) The pharmacist in charge of the drug outlet where a controlled substance is
804	dispensed shall submit the data described in this section to the division:
805	[(a)] (i) in accordance with the requirements of this section;
806	[(b)] (ii) in accordance with the procedures established by the division; and
807	[(c)] <u>(iii)</u> in the format established by the division.
808	(b) A dispensing medical practitioner licensed under Chapter 17b, Part 8, Dispensing
809	Medical Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, shall comply with
810	the provisions of this section and the dispensing medical practitioner shall assume the duties of
811	the pharmacist under this chapter.
812	(2) The pharmacist described in Subsection (1) shall, for each controlled substance
813	dispensed by a pharmacist under the pharmacist's supervision other than those dispensed for an
814	inpatient at a health care facility, submit to the division the following information:
815	(a) the name of the prescribing practitioner;
816	(b) the date of the prescription;
817	(c) the date the prescription was filled;
818	(d) the name of the individual for whom the prescription was written;
819	(e) positive identification of the individual receiving the prescription, including the
820	type of identification and any identifying numbers on the identification;
821	(f) the name of the controlled substance;
822	(g) the quantity of the controlled substance prescribed;
823	(h) the strength of the controlled substance;
824	(i) the quantity of the controlled substance dispensed;
825	(j) the dosage quantity and frequency as prescribed;
826	(k) the name of the drug outlet dispensing the controlled substance;
827	(l) the name of the pharmacist dispensing the controlled substance; and
828	(m) other relevant information as required by division rule.
829	(3) (a) The division shall make rules, in accordance with Title 63G, Chapter 3, Utah
830	Administrative Rulemaking Act, to establish the electronic format in which the information
831	required under this section shall be submitted to the division.

832	(b) The division shall ensure that the database system records and maintains for
833	reference:
834	(i) the identification of each individual who requests or receives information from the
835	database;
836	(ii) the information provided to each individual; and
837	(iii) the date and time that the information is requested or provided.
838	Section 15. Section 58-67-502 is amended to read:
839	58-67-502. Unprofessional conduct.
840	"Unprofessional conduct" includes, in addition to the definition in Section 58-1-501:
841	(1) using or employing the services of any individual to assist a licensee in any manner
842	not in accordance with the generally recognized practices, standards, or ethics of the
843	profession, state law, or division rule;
844	(2) making a material misrepresentation regarding the qualifications for licensure under
845	Section 58-67-302.7; or
846	(3) violating the dispensing requirements of Section 58-17b-309 or [58-17b-309.5]
847	Chapter 17b, Part 8, Dispensing Medical Practitioner and Dispensing Medical Practitioner
848	Clinic Pharmacy, if applicable.
849	Section 16. Section 58-68-502 is amended to read:
850	58-68-502. Unprofessional conduct.
851	"Unprofessional conduct" includes, in addition to the definition in Section 58-1-501:
852	(1) using or employing the services of any individual to assist a licensee in any manner
853	not in accordance with the generally recognized practices, standards, or ethics of the
854	profession, state law, or division rule; or
855	(2) violating the dispensing requirements of Section 58-17b-309 or [58-17b-309.5]
856	Chapter 17b, Part 8, Dispensing Medical Practitioner and Dispensing Medical Practitioner
857	Clinic Pharmacy, if applicable.
858	Section 17. Section 58-70a-502 is amended to read:
859	58-70a-502. Unlawful conduct.
860	"Unlawful conduct" includes[: (1)] engaging in practice as a licensed physician assistant
861	while not under the supervision of a supervising physician or substitute supervising physician[;
862	or] <u>.</u>

803	[(2) Violating the drug dispensing requirements of Section 38-170-309 of
864	58-17b-309.5, if applicable.]
865	Section 18. Section 58-70a-503 is amended to read:
866	58-70a-503. Unprofessional conduct.
867	"Unprofessional conduct" includes:
868	(1) violation of a patient confidence to any person who does not have a legal right and
869	a professional need to know the information concerning the patient;
870	(2) knowingly prescribing, selling, giving away, or directly or indirectly administering,
871	or offering to prescribe, sell, furnish, give away, or administer any prescription drug except for
872	a legitimate medical purpose upon a proper diagnosis indicating use of that drug in the amounts
873	prescribed or provided;
874	(3) prescribing prescription drugs for himself or administering prescription drugs to
875	himself, except those that have been legally prescribed for him by a licensed practitioner and
876	that are used in accordance with the prescription order for the condition diagnosed;
877	(4) failure to maintain at the practice site a delegation of services agreement that
878	accurately reflects current practices;
879	(5) failure to make the delegation of services agreement available to the division for
880	review upon request; [and]
881	(6) in a practice that has physician assistant ownership interests, failure to allow the
882	supervising physician the independent final decision making authority on patient treatment
883	decisions, as set forth in the delegation of services agreement or as defined by rule[-]; and
884	(7) violating the dispensing requirements of Chapter 17b, Part 8, Dispensing Medical
885	Practitioner and Dispensing Medical Practitioner Clinic Pharmacy, if applicable.
886	Section 19. Section 58-83-502 is amended to read:
887	58-83-502. Unprofessional conduct.
888	"Unprofessional conduct" includes, in addition to the definition in Section 58-1-501 and
889	as may be further defined by administrative rule:
890	(1) online prescribing, dispensing, or facilitation with respect to a person under the age
891	of 18 years;
892	(2) using the name or official seal of the state, the Utah Department of Commerce, or
893	the Utah Division of Occupational and Professional Licensing, or their boards, in an

894	unauthorized manner;
895	(3) failing to respond promptly to a request by the division for information including:
896	(a) an audit of the website; or
897	(b) records of the online prescriber, the Internet facilitator, or the online contract
898	pharmacy;
899	(4) using an online prescriber, online contract pharmacy, or Internet facilitator without
900	approval of the division;
901	(5) failing to inform a patient of the patient's freedom of choice in selecting who will
902	dispense a prescription in accordance with Subsection 58-83-305(1)(n);
903	(6) failing to keep the division informed of the name and contact information of the
904	Internet facilitator or online contract pharmacy; and
905	(7) violating the dispensing and labeling requirements of [Section 58-17b-309] Chapter
906	17b, Part 8, Dispensing Medical Practitioner and Dispensing Medical Practitioner Clinic
907	Pharmacy.
908	Section 20. Section 63I-1-258 is amended to read:
909	63I-1-258. Repeal dates, Title 58.
910	(1) Title 58, Chapter 13, Health Care Providers Immunity from Liability Act, is
911	repealed July 1, 2016.
912	(2) Title 58, Chapter 15, Health Facility Administrator Act, is repealed July 1, 2015.
913	(3) [Section 58-17b-309.5 is repealed July 1, 2015. (4)] Title 58, Chapter 20a,
914	Environmental Health Scientist Act, is repealed July 1, 2018.
915	[(5)] (4) Title 58, Chapter 40, Recreational Therapy Practice Act, is repealed July 1,
916	2023.
917	[(6)] (5) Title 58, Chapter 41, Speech-Language Pathology and Audiology Licensing
918	Act, is repealed July 1, 2019.
919	[(7)] <u>(6)</u> Title 58, Chapter 42a, Occupational Therapy Practice Act, is repealed July 1,
920	2015.
921	[(8)] <u>(7)</u> Title 58, Chapter 46a, Hearing Instrument Specialist Licensing Act, is
922	repealed July 1, 2023.
923	[(9)] (8) Title 58, Chapter 47b, Massage Therapy Practice Act, is repealed July 1, 2014
924	[(10)] (9) Section 58-69-302.5 is repealed on July 1, 2015.

02-07-14 4:16 PM

1st Sub. (Green) S.B. 55

925	[(11)] (10) Title 58, Chapter 72, Acupuncture Licensing Act, is repealed July 1, 2017.
926	Section 21. Repealer.
927	This bill repeals:
928	Section 58-17b-309.5, Exemption for prescribing practitioner of cancer drug
929	regimen Division study of dispensing practitioners.
930	Section 22. Effective date.
931	This bill takes effect on July 1, 2014.